04.04.2011 • News

Solvay Bids €3.4 Billion for France's Rhodia

Belgian chemicals and plastics maker Solvay said on Monday it will buy French chemicals company Rhodia, valuing the firm at €3.4 billion and ending a year-long hunt for a takeover deal.

Solvay, which sold its drugs unit to its U.S. partner Abbott Laboratories in September 2009 for €4.5 billion, said it would bid €31.60 per share for Rhodia in a deal that was unanimously recommended by Rhodia's board of directors.

The offer price constitutes a premium of 50% compared to the latest closing share price of Rhodia, giving an enterprise value of €6.6 billion and a recurring earnings before interest, tax, depreciation and amortization of 7.3 times.

Solvay said the acquisition of Rhodia will be earnings accretive from the first year and the deal will be fully financed by the company's cash resources.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read